INSTI, Tenofovir-Free Regimen DOR/ISL Gains FDA Approval for HIV This fixed-dose, 2-drug combination is a once-daily, ...

Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-RAnnounced positive ...

Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patientsOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE ...

Six-month data from adult Cohort 4 show structural and functional improvements and a favorable safety profile; early safety data from pediatric ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the independent Data ...

Seeed Studio reBot Arm B601-DM is a fully open-source 6-axis robotic arm (plus a parallel gripper) designed to lower the barrier to entry for embodied AI learning and teleoperation. Built around ...

Visa (V) started an exchange offer that allows class B shareholders to convert more of their Visa shares to freely tradeable shares, the company said on Monday. Under the offer, Visa (V) will offer a ...

*A gene therapy that may eliminate, or significantly reduce, the need for daily insulin injections is preparing to enter human trials for the first time, offering fresh hope to hundreds of thousands ...

The Artemis 2 astronauts are now on their way to the Moon. At 7:57 p.m. ET, the Orion spacecraft completed a translunar injection burn, making it the first crewed spacecraft to depart low-Earth orbit ...

A new gene therapy is giving people born deaf the chance to hear, often within just weeks. In a small but groundbreaking study, researchers delivered a working copy of a key hearing gene directly into ...

"Humanity has once again shown what we are capable of, and it's your hopes for the future that carry us now on this journey around the moon." When you purchase through links on our site, we may earn ...

NICE has recommended Wegovy ® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or ...